Inventiva's 15min Chart Triggers KDJ Golden Cross, Bullish Marubozu Formation

Inventiva's 15-minute chart recently experienced a notable technical indicator, the KDJ Golden Cross, accompanied by a Bullish Marubozu at 09/02/2025 12:15. This signifies a shift in the momentum of the stock price towards an upward trajectory, with potential for further growth. The current market dynamics suggest that buyers are in control, and it is likely that bullish momentum will persist.

Inventiva (NASDAQ: IVA) stock experienced a notable surge on September 2, 2025, following Piper Sandler's initiation of coverage with an Overweight rating and a $26.00 price target. The stock has shown impressive momentum, gaining over 88% in the past year and trading near its 52-week high of $4.79 [1].

Piper Sandler highlighted Inventiva's lead asset, lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH). The research firm expects Phase 3 NATiV3 topline results in the second half of 2026, which could be a significant stock-moving event [1].

Moreover, Inventiva's current market capitalization of approximately $650 million represents a 14-times valuation gap compared to Madrigal Pharmaceuticals' $9.2 billion valuation in the MASH treatment space. This valuation disconnect provides investors with a compelling buying opportunity [1].

In addition to the analyst's bullish view, Inventiva's stock chart recently displayed a notable technical indicator, the KDJ Golden Cross, accompanied by a Bullish Marubozu on September 2, 2025, at 12:15. This signifies a shift in the momentum of the stock price towards an upward trajectory, with potential for further growth. The current market dynamics suggest that buyers are in control, and it is likely that bullish momentum will persist [2].

The recent surge in Inventiva's stock price can be attributed to the combination of Piper Sandler's bullish view and the positive technical indicators. Investors should closely monitor the upcoming Phase 3 NATiV3 trial results for lanifibranor, as they could significantly impact the stock's performance.

References:
[1] https://www.investing.com/news/analyst-ratings/piper-sandler-initiates-inventiva-stock-with-overweight-rating-on-mash-potential-93CH-4212184
[2] https://seekingalpha.com/news/4489664-inventiva-stock-surges-piper-sandler-bullish-view